Statin Therapy for Diabetics with Low ASCVD Risk

Recommendations Based on Age and Risk Factors

The American Diabetes Association recommends that all patients with diabetes aged 40-75 years should be on moderate-intensity statin therapy for primary prevention of cardiovascular disease, regardless of their ASCVD risk status 1, 2
For diabetic patients aged 40-75 years without established ASCVD, moderate-intensity statin therapy is recommended, regardless of baseline LDL cholesterol levels 1, 3
High-intensity statin therapy should be considered for those with additional ASCVD risk factors, with a goal to reduce LDL cholesterol by ≥50% from baseline and achieve an LDL cholesterol goal of <70 mg/dL 1, 2, 4

Moderate-intensity statin options include Atorvastatin 10-20 mg, Rosuvastatin 5-10 mg, Pravastatin 40-80 mg, and Fluvastatin XL 80 mg 1, 3, 4
High-intensity statin options include Atorvastatin 40-80 mg, Rosuvastatin 20-40 mg, Simvastatin 20-40 mg, Lovastatin 40 mg, and Pitavastatin 1-4 mg 1, 3

Multiple clinical trials have demonstrated beneficial effects of statin therapy on ASCVD outcomes in patients with diabetes, with a 9% reduction in all-cause mortality and 13% reduction in vascular mortality for each 39 mg/dL reduction in LDL cholesterol 3, 6
The cardiovascular benefit is linearly related to LDL cholesterol reduction without a low threshold below which there is no benefit 3

The American College of Cardiology recommends obtaining a lipid profile at initiation of statin therapy, 4-12 weeks after initiation or dose change, and annually thereafter 7, 8
Monitoring for statin-related side effects and adjusting dosing as needed is also recommended 3